Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 4/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004254 | 0.73 | RORC (0.46) | NR3C1PGRRORCL3MBTL1 | |
| SCHEMBL5892016 | 0.72 | CYP19A1 (0.57) | NR3C2SLC22A12ALPLSMN1; SMN2ALDH1A1 | |
| SCHEMBL12491364 | 0.72 | SMN1; SMN2 (0.54) | SLC22A12ALPLSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL5166693 | 0.72 | NR3C2 (0.57) | NR3C2SMN1; SMN2BRD4ALDH1A1L3MBTL1 | |
| SCHEMBL4971940 | 0.71 | RORC (0.49) | NR3C1NR3C2PGRRORC | |
| SCHEMBL29615607 | 0.69 | NR3C1 (0.51) | NR3C1PGRRORC | |
| SCHEMBL20577702 | 0.69 | NR3C1 (0.51) | NR3C1PGRRORC | |
| SCHEMBL2004916 | 0.69 | RORC (0.46) | NR3C1PGRRORC | |
| SCHEMBL17101815 | 0.68 | LMNA (0.43) | SLC22A12ALPLSMN1; SMN2L3MBTL1 | |
| SCHEMBL1940423 | 0.67 | PDE4A (0.45) | NR3C1PGRRORCSLC22A12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.